TAIPEI, Taiwan I August 4, 2025 I Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New ...

HONG KONG, China I August 4, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II ...

STUTTGART, Germany I August 04, 2025 I La Merie Publishing released its newest product entitled: DLL3-Targeted Immunotherapy: a Competitor Analysis.

NEW YORK, NY, USA I August 01, 2025 I Spine BioPharma, Inc. announced today the Phase 3 MODEL trial (MOderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine) evaluating SB-01, a TGF ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over ...

SHANGHAI, China I August 1, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its ...

The SGX945 proof of concept pilot study was an open-label study that enrolled 8 patients age 18 years or older with mild to ...

STUTTGART, Germany I August 02, 2025 I La Merie Publishing released its newest product entitled: B7-H3-Targeted Immunotherapy: a Competitor Analysis.

LOS ANGELES, CA, USA I July 30, 2025 I Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company ...

EMERYVILLE, CA, USA I July 31, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...

WALTHAM, MA, USA I July 28, 2025 I Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has ...

Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of ...